Vers une médecine personnalisée sous anti-TNF ? : pas encore… (notice n° 1673140)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01928cam a2200301 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20260301001108.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Roblin, Xavier |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Vers une médecine personnalisée sous anti-TNF ? : pas encore… |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 6 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | There is a link between the presence of the HLA DQA1-05 allele and the development of anti-TNF antibodies. Testing for the HLA DQA1-05 variant makes it possible to isolate patients at high immunogenic risk under anti-TNF therapy, but sensitivity and specificity are insufficient to propose precise algorithms based on the result. This test remains a decision-making tool. Elevated IFX clearance identifies patients at greatest risk of colectomy in the follow-up of severe acute colitis. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Il existe un lien entre la présence de l’allèle HLA DQA1-05 et le développement d’anticorps anti-TNF. La recherche du variant HLA DQA1-05 permet d’isoler les patients à fort risque immunogène sous anti-TNF mais les sensibilité et spécificité sont insuffisantes pour proposer des algorithmes précis en fonction du résultat. Ce test reste un outil d’aide à la décision. L’élévation de la clairance de l’IFX identifie les patients les plus à risque de colectomie dans le suivi de colite aiguë grave. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | anticorps anti-TNF |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | biothérapie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | clairance de l’infliximab |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | MICI |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | variant HLA DQA1-05 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | anti-TNF antibody |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | biotherapy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | HLA DQA1-05 variant |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | IBD |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | infliximab clearance |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Barrau, Mathilde |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 31 | 1 | 2024-01-01 | p. 29-32 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2024-1-page-29?lang=fr&redirect-ssocas=7080">https://stm.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2024-1-page-29?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux